Implicit Bioscience is an unlisted public company based in Brisbane and Seattle. It was founded in 2005 by a number of biopharma veterans including Prof. Peter Andrews AO and Prof. Ian Frazer AC FRS; the company’s mission is to apply groundbreaking immunotherapy to treat serious and life-threatening diseases with few or no effective treatments. Implicit Bioscience holds worldwide rights to IC14 and is developing it in the new field of immunoneurology for a range of neurodegenerative and neurotraumatic disease indications. IC14 is a biologic monoclonal antibody drug that inactivates CD14 on immune cells and in circulation. CD14 is a master regulator of the immune response that is also a key organiser of responses by the brain’s most common immune cell to infection and injury. Hyper-activated CD14 results in damaging inflammation that kills healthy brain and other cells in diseases such as MND/ALS.
